Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition (Tables)

v3.19.3
Revenue Recognition (Tables)
9 Months Ended
Sep. 30, 2019
Revenue Recognition [Abstract]  
Schedule of revenue recognition

Revenue by Service Line

 

  Three Months Ended
September 30,
 
  2019     2018  
Products:              
Disposable products:              
Functional neurosurgery $ 1,854,251     $ 1,448,850  
Biologics and drug delivery   491,257       190,993  
Therapy   64,095       -  
Capital equipment   184,825       99,961  
Total product revenue   2,594,428       1,739,804  
Services:              
Capital equipment and other   210,538       62,238  
Biologics and drug delivery   72,500       5,000  
Therapy   50,000       -  
Total service revenue   333,038       67,238  
Total revenue $ 2,927,466     $ 1,807,042  

 

  Nine Months Ended
September 30,
 
  2019     2018  
Products:              
Disposable products:              
Functional neurosurgery $ 5,212,460     $ 3,787,712  
Biologics and drug delivery   957,673       483,251  
Therapy   81,925       -  
Capital equipment   700,517       420,039  
Total product revenue   6,952,575       4,691,002  
Services:              
Capital equipment and other   515,695       218,742  
Biologics and drug delivery   335,500       167,000  
Therapy   202,612       -  
Total service revenue   1,053,807       385,742  
Total revenue $ 8,006,382     $ 5,076,744